{"groups":[{"description":"Rituximab, methotrexate, temozolomide 100 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"FG000","title":"Phase I: Temozolomide 100 mg"},{"description":"Rituximab, methotrexate, temozolomide 150 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"FG001","title":"Phase I: Temozolomide 150 mg"},{"description":"Rituximab, methotrexate, temozolomide 200 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"FG002","title":"Phase I: Temozolomide 200 mg"},{"description":"Rituximab, methotrexate, temozolomide 100 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"FG003","title":"Phase II: Temozolomide 100 mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase I: Dose Level 1"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase I: Dose Level 2"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG003","numSubjects":"47"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase II: Dose Level 2"}]}